RU2015120217A - Замещенные 1,6-нафтиридины - Google Patents
Замещенные 1,6-нафтиридины Download PDFInfo
- Publication number
- RU2015120217A RU2015120217A RU2015120217A RU2015120217A RU2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A RU 2015120217 A RU2015120217 A RU 2015120217A
- Authority
- RU
- Russia
- Prior art keywords
- naphthyridine
- carboxamide
- chlorophenyl
- phenyl
- methylsulfonyl
- Prior art date
Links
- -1 cyano, hydroxy Chemical group 0.000 claims 152
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 102000014461 Ataxins Human genes 0.000 claims 4
- 108010078286 Ataxins Proteins 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 4
- 206010011878 Deafness Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 4
- 208000009205 Tinnitus Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000029560 autism spectrum disease Diseases 0.000 claims 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 4
- 230000037326 chronic stress Effects 0.000 claims 4
- 230000010370 hearing loss Effects 0.000 claims 4
- 231100000888 hearing loss Toxicity 0.000 claims 4
- 208000016354 hearing loss disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 208000019906 panic disease Diseases 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 231100000886 tinnitus Toxicity 0.000 claims 4
- 208000011641 Spinocerebellar disease Diseases 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- MZTCGZQAMJDRJF-UHFFFAOYSA-N 8-(2,4-dichlorophenyl)-n-(3-hydroxy-3-methylbutan-2-yl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=C(Cl)C=C1Cl MZTCGZQAMJDRJF-UHFFFAOYSA-N 0.000 claims 2
- AEOSRBZVUCBDDV-UHFFFAOYSA-N 8-(2,4-difluorophenyl)-n-[(4-methylsulfonylphenyl)methyl]-1,6-naphthyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CNC(=O)C1=CC=C(C=NC=C2C=3C(=CC(F)=CC=3)F)C2=N1 AEOSRBZVUCBDDV-UHFFFAOYSA-N 0.000 claims 2
- KABMWMZOLXCCEI-UHFFFAOYSA-N 8-(2-chlorophenyl)-n-(3-hydroxy-3-methylbutan-2-yl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=CC=C1Cl KABMWMZOLXCCEI-UHFFFAOYSA-N 0.000 claims 2
- KDPMZJSWEDEULR-UHFFFAOYSA-N 8-(2-fluorophenyl)-n-[1-(4-methylsulfonylphenyl)ethyl]-1,6-naphthyridine-2-carboxamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(C)NC(=O)C(N=C12)=CC=C1C=NC=C2C1=CC=CC=C1F KDPMZJSWEDEULR-UHFFFAOYSA-N 0.000 claims 2
- DQMMMPXPFGNBKQ-UHFFFAOYSA-N 8-(3,4-difluorophenyl)-n-[(4-methylsulfonylphenyl)methyl]-1,6-naphthyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CNC(=O)C1=CC=C(C=NC=C2C=3C=C(F)C(F)=CC=3)C2=N1 DQMMMPXPFGNBKQ-UHFFFAOYSA-N 0.000 claims 2
- DNTNKPLCSNWTTP-UHFFFAOYSA-N 8-(3,4-difluorophenyl)-n-[1-(4-methylsulfonylphenyl)ethyl]-1,6-naphthyridine-2-carboxamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(C)NC(=O)C(N=C12)=CC=C1C=NC=C2C1=CC=C(F)C(F)=C1 DNTNKPLCSNWTTP-UHFFFAOYSA-N 0.000 claims 2
- KEGAUXYYZCAWBB-UHFFFAOYSA-N 8-(3-fluorophenyl)-n-[1-(4-methylsulfonylphenyl)ethyl]-1,6-naphthyridine-2-carboxamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(C)NC(=O)C(N=C12)=CC=C1C=NC=C2C1=CC=CC(F)=C1 KEGAUXYYZCAWBB-UHFFFAOYSA-N 0.000 claims 2
- LQQGOINWQUOPHG-UHFFFAOYSA-N 8-(4-chloro-2-fluorophenyl)-N-(2-methylsulfonylethyl)-1,6-naphthyridine-2-carboxamide 8-[2-(dimethylamino)pyridin-4-yl]-1,6-naphthyridine-2-carboxamide Chemical compound CN(C1=NC=CC(=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N)C.ClC1=CC(=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCCS(=O)(=O)C)F LQQGOINWQUOPHG-UHFFFAOYSA-N 0.000 claims 2
- MROPOPXYFUVFQG-UHFFFAOYSA-N 8-(4-chloro-3-fluorophenyl)-n-(3-hydroxy-3-methylbutan-2-yl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=C(Cl)C(F)=C1 MROPOPXYFUVFQG-UHFFFAOYSA-N 0.000 claims 2
- KZKBFJUVVOQZBV-UHFFFAOYSA-N 8-(4-chlorophenyl)-n-(3-hydroxy-3-methylbutan-2-yl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=C(Cl)C=C1 KZKBFJUVVOQZBV-UHFFFAOYSA-N 0.000 claims 2
- POUQPSQZQQDXGE-UHFFFAOYSA-N 8-(4-chlorophenyl)-n-[(3-methylsulfonylphenyl)methyl]-1,6-naphthyridine-2-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC(CNC(=O)C=2N=C3C(C=4C=CC(Cl)=CC=4)=CN=CC3=CC=2)=C1 POUQPSQZQQDXGE-UHFFFAOYSA-N 0.000 claims 2
- AGWPTSQGMOLJOE-UHFFFAOYSA-N 8-(6-chloropyridin-2-yl)-N-(3-hydroxy-3-methylbutan-2-yl)-1,6-naphthyridine-2-carboxamide N-(3-hydroxy-3-methylbutan-2-yl)-8-(2-methylphenyl)-1,6-naphthyridine-2-carboxamide Chemical compound OC(C(C)NC(=O)C1=NC2=C(C=NC=C2C=C1)C1=C(C=CC=C1)C)(C)C.ClC1=CC=CC(=N1)C=1C=NC=C2C=CC(=NC12)C(=O)NC(C)C(C)(C)O AGWPTSQGMOLJOE-UHFFFAOYSA-N 0.000 claims 2
- OQEKEZIVMIUVAV-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-n-(3-hydroxy-3-methylbutan-2-yl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=C(Cl)N=C1 OQEKEZIVMIUVAV-UHFFFAOYSA-N 0.000 claims 2
- JKSHBKNRUQOZQZ-UHFFFAOYSA-N 8-[2-methyl-4-(trifluoromethyl)phenyl]-1,6-naphthyridine-2-carboxamide Chemical compound CC1=CC(C(F)(F)F)=CC=C1C1=CN=CC2=CC=C(C(N)=O)N=C12 JKSHBKNRUQOZQZ-UHFFFAOYSA-N 0.000 claims 2
- YQQFZTGCLBNNNB-UHFFFAOYSA-N C(C(C)C)C=1C=NC=C2C=CC(=NC12)C(=O)N.FC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCCS(=O)(=O)C Chemical compound C(C(C)C)C=1C=NC=C2C=CC(=NC12)C(=O)N.FC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCCS(=O)(=O)C YQQFZTGCLBNNNB-UHFFFAOYSA-N 0.000 claims 2
- JZHWRGMPYWZFCJ-UHFFFAOYSA-N COCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=NC=C1.C(C1=CC=CC=C1)NC(=O)C1=NC2=C(C=NC=C2C=C1)C=1C=NC=CC1 Chemical compound COCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=NC=C1.C(C1=CC=CC=C1)NC(=O)C1=NC2=C(C=NC=C2C=C1)C=1C=NC=CC1 JZHWRGMPYWZFCJ-UHFFFAOYSA-N 0.000 claims 2
- UAWPWGACAZGCKN-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N(C)C1CC1.ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=NC=NC=C1 Chemical compound ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N(C)C1CC1.ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=NC=NC=C1 UAWPWGACAZGCKN-UHFFFAOYSA-N 0.000 claims 2
- AVXIREUGNHMOQU-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=CC=C(C=C1)S(=O)(=O)C.ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NNS(=O)(=O)C Chemical compound ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=CC=C(C=C1)S(=O)(=O)C.ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NNS(=O)(=O)C AVXIREUGNHMOQU-UHFFFAOYSA-N 0.000 claims 2
- VPLSDXGMXPUAHQ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=NC=C(N=C1)C.ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=C(C=CC=C1)OC Chemical compound ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=NC=C(N=C1)C.ClC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NCC1=C(C=CC=C1)OC VPLSDXGMXPUAHQ-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- RPEJEUTVNYHAOG-UHFFFAOYSA-N [8-(4-chloro-2-fluorophenyl)-1,6-naphthyridin-2-yl]-(3-hydroxypyrrolidin-1-yl)methanone Chemical compound C1C(O)CCN1C(=O)C1=CC=C(C=NC=C2C=3C(=CC(Cl)=CC=3)F)C2=N1 RPEJEUTVNYHAOG-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- ARJNKELYUPCAJP-UHFFFAOYSA-N n-(3-hydroxy-3-methylbutan-2-yl)-8-(3,4,5-trifluorophenyl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC(F)=C(F)C(F)=C1 ARJNKELYUPCAJP-UHFFFAOYSA-N 0.000 claims 2
- RYKCSGMKLOYCIY-UHFFFAOYSA-N n-(3-hydroxy-3-methylbutan-2-yl)-8-[4-(2,2,2-trifluoroethoxy)phenyl]-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=C(OCC(F)(F)F)C=C1 RYKCSGMKLOYCIY-UHFFFAOYSA-N 0.000 claims 2
- SJIJSUIQHRSJRY-UHFFFAOYSA-N n-[3-(3,5-dimethylpyrazol-1-yl)propyl]-8-(4-methoxyphenyl)-1,6-naphthyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CN=CC2=CC=C(C(=O)NCCCN3C(=CC(C)=N3)C)N=C12 SJIJSUIQHRSJRY-UHFFFAOYSA-N 0.000 claims 2
- ZRAOHKXWJGFPNZ-UHFFFAOYSA-N tert-butyl 4-[8-(4-chlorophenyl)-1,6-naphthyridine-2-carbonyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC=C(C=NC=C2C=3C=CC(Cl)=CC=3)C2=N1 ZRAOHKXWJGFPNZ-UHFFFAOYSA-N 0.000 claims 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- MUGSKSNNEORSJG-UHFFFAOYSA-N 3174-74-1 Chemical compound C1CC=CCO1 MUGSKSNNEORSJG-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- XCRUTZNVFSAVAK-UHFFFAOYSA-N 8-(2,4-difluorophenyl)-n-[1-(4-methylsulfonylphenyl)ethyl]-1,6-naphthyridine-2-carboxamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(C)NC(=O)C(N=C12)=CC=C1C=NC=C2C1=CC=C(F)C=C1F XCRUTZNVFSAVAK-UHFFFAOYSA-N 0.000 claims 1
- PNWBOXQOXATAEP-UHFFFAOYSA-N 8-(3-methoxyphenyl)-1,6-naphthyridine-2-carboxamide Chemical compound COC1=CC=CC(C=2C3=NC(=CC=C3C=NC=2)C(N)=O)=C1 PNWBOXQOXATAEP-UHFFFAOYSA-N 0.000 claims 1
- YJVAXPJSBKTUKE-UHFFFAOYSA-N 8-(4-chlorophenyl)-n-propan-2-yl-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C)=CC=C2C=NC=C1C1=CC=C(Cl)C=C1 YJVAXPJSBKTUKE-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- VCBFZFMNKRLCFW-UHFFFAOYSA-N 8-[4-(dimethylsulfamoyl)phenyl]-1,6-naphthyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=CN=CC2=CC=C(C(N)=O)N=C12 VCBFZFMNKRLCFW-UHFFFAOYSA-N 0.000 claims 1
- QUZUKRHLANKGSL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=C(C=C1)OC.COC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N1CCCCC1 Chemical compound C(C1=CC=CC=C1)NC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=C(C=C1)OC.COC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N1CCCCC1 QUZUKRHLANKGSL-UHFFFAOYSA-N 0.000 claims 1
- GDZJTMDPIPJSIL-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)C=1C=NC=C2C=CC(=NC12)C(=O)N.ClC1=CC=C(C=N1)C=1C=NC=C2C=CC(=NC12)C(=O)N Chemical compound ClC1=C(C=CC(=C1)Cl)C=1C=NC=C2C=CC(=NC12)C(=O)N.ClC1=CC=C(C=N1)C=1C=NC=C2C=CC(=NC12)C(=O)N GDZJTMDPIPJSIL-UHFFFAOYSA-N 0.000 claims 1
- QTRXTGLZRFJPME-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NC(C)C1=CC=C(C=C1)S(=O)(=O)C.CN(S(=O)(=O)C1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N)C Chemical compound FC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)NC(C)C1=CC=C(C=C1)S(=O)(=O)C.CN(S(=O)(=O)C1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N)C QTRXTGLZRFJPME-UHFFFAOYSA-N 0.000 claims 1
- XGJIHTVPOFPWCY-UHFFFAOYSA-N N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=C(C=CC=C1)OC.N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC(=CC=C1)OC Chemical compound N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=C(C=CC=C1)OC.N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC(=CC=C1)OC XGJIHTVPOFPWCY-UHFFFAOYSA-N 0.000 claims 1
- ZHUMKLUUZYMKRD-UHFFFAOYSA-N N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=NC=C1.N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=C(C=CC=C1)Cl Chemical compound N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=NC=C1.N1(C=NC=C1)CCCNC(=O)C1=NC2=C(C=NC=C2C=C1)C1=C(C=CC=C1)Cl ZHUMKLUUZYMKRD-UHFFFAOYSA-N 0.000 claims 1
- SPLNJEKIOUIEAE-UHFFFAOYSA-N NCC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N.C(#N)C1=CC=C(C=C1)C=1C=NC=C2C=C(C(=NC12)C(=O)N)C Chemical compound NCC1=CC=C(C=C1)C=1C=NC=C2C=CC(=NC12)C(=O)N.C(#N)C1=CC=C(C=C1)C=1C=NC=C2C=C(C(=NC12)C(=O)N)C SPLNJEKIOUIEAE-UHFFFAOYSA-N 0.000 claims 1
- IUBTUSZOFISYID-UHFFFAOYSA-N OC(C(C)NC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=C(C=C1)C(F)(F)F)(C)C.ClC1=C(C=CC(=C1)Cl)C=1C=NC=C2C=CC(=NC12)C(=O)N Chemical compound OC(C(C)NC(=O)C1=NC2=C(C=NC=C2C=C1)C1=CC=C(C=C1)C(F)(F)F)(C)C.ClC1=C(C=CC(=C1)Cl)C=1C=NC=C2C=CC(=NC12)C(=O)N IUBTUSZOFISYID-UHFFFAOYSA-N 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IWDXJDXDAXMYGK-UHFFFAOYSA-N n-(2-hydroxyethyl)-8-(3-hydroxyphenyl)-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NCCO)=CC=C2C=NC=C1C1=CC=CC(O)=C1 IWDXJDXDAXMYGK-UHFFFAOYSA-N 0.000 claims 1
- GQUUFNXTRMDYPA-UHFFFAOYSA-N n-(3-hydroxy-3-methylbutan-2-yl)-8-[4-(trifluoromethyl)phenyl]-1,6-naphthyridine-2-carboxamide Chemical compound C12=NC(C(=O)NC(C)C(C)(C)O)=CC=C2C=NC=C1C1=CC=C(C(F)(F)F)C=C1 GQUUFNXTRMDYPA-UHFFFAOYSA-N 0.000 claims 1
- HPORJQKRIZBDHJ-UHFFFAOYSA-N n-(3-imidazol-1-ylpropyl)-8-pyridin-4-yl-1,6-naphthyridine-2-carboxamide Chemical compound C=1C=C2C=NC=C(C=3C=CN=CC=3)C2=NC=1C(=O)NCCCN1C=CN=C1 HPORJQKRIZBDHJ-UHFFFAOYSA-N 0.000 claims 1
- YJPZLVHFCRPICW-UHFFFAOYSA-N n-benzyl-8-(4-methoxyphenyl)-n-methyl-1,6-naphthyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CN=CC2=CC=C(C(=O)N(C)CC=3C=CC=CC=3)N=C12 YJPZLVHFCRPICW-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12193311 | 2012-11-20 | ||
| EP12193311.3 | 2012-11-20 | ||
| PCT/EP2013/074012 WO2014079787A1 (en) | 2012-11-20 | 2013-11-18 | Substituted 1,6-naphthyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015120217A true RU2015120217A (ru) | 2017-01-10 |
Family
ID=47189816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120217A RU2015120217A (ru) | 2012-11-20 | 2013-11-18 | Замещенные 1,6-нафтиридины |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9657014B2 (OSRAM) |
| EP (1) | EP2922540A1 (OSRAM) |
| JP (1) | JP2016505534A (OSRAM) |
| KR (1) | KR20150085538A (OSRAM) |
| CN (1) | CN104812387A (OSRAM) |
| AR (1) | AR093519A1 (OSRAM) |
| BR (1) | BR112015011094A2 (OSRAM) |
| CA (1) | CA2890685A1 (OSRAM) |
| HK (1) | HK1207317A1 (OSRAM) |
| MX (1) | MX2015006364A (OSRAM) |
| RU (1) | RU2015120217A (OSRAM) |
| TW (1) | TW201425312A (OSRAM) |
| WO (1) | WO2014079787A1 (OSRAM) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2838857C2 (ru) * | 2019-01-03 | 2025-04-22 | Юниверсити Оф Питтсбург - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Способы и материалы для повышения уровней полипептида фактора транскрипции eb |
| US12286442B2 (en) | 2019-01-03 | 2025-04-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI529171B (zh) | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| JP2017522324A (ja) * | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| CA2974874A1 (en) * | 2015-02-11 | 2016-08-18 | Basilea Pharmaceutica International AG | Substituted mono- and polyazanaphthalene derivatives and their use |
| CN106008340B (zh) | 2015-03-24 | 2020-03-17 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| MY194461A (en) | 2015-11-06 | 2022-11-30 | Neurocrine Biosciences Inc | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| EA039638B1 (ru) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Антагонисты мускаринового рецептора 4 и способы их применения |
| EP3591040A4 (en) | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| WO2022133303A1 (en) * | 2020-12-18 | 2022-06-23 | The Scripps Research Institute | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders |
| WO2025252732A1 (en) * | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Nitrogen-containing 6-membered bicyclic derivatives with microbiocidal activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9605437D0 (en) | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
| ATE249219T1 (de) * | 1997-12-11 | 2003-09-15 | Iaf Biochem Int | Antivirale verbindungen |
| AU2002218902A1 (en) | 2000-12-27 | 2002-07-08 | Shire Biochem Inc. | Macrocyclic anti-viral compounds |
| WO2006017672A2 (en) * | 2004-08-03 | 2006-02-16 | Serenex Inc. | 2, 8-disubstituted naphthyridine derivatives |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| NZ593996A (en) * | 2009-01-19 | 2012-10-26 | Daiichi Sankyo Co Ltd | Naphthyridine-carboxamide and isoquinoline-carboxamide derivatives for treating osteoporosis |
| CA2754058A1 (en) * | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| CA2758144C (en) * | 2009-04-06 | 2014-05-13 | Daiichi Sankyo Company, Limited | Cyclic compound having substituted phenyl group |
| CA2804161A1 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| JP2012036168A (ja) | 2010-07-15 | 2012-02-23 | Daiichi Sankyo Co Ltd | ヘテロ原子を有する環状化合物を含有する医薬組成物 |
-
2013
- 2013-11-18 CA CA2890685A patent/CA2890685A1/en not_active Abandoned
- 2013-11-18 BR BR112015011094A patent/BR112015011094A2/pt not_active IP Right Cessation
- 2013-11-18 WO PCT/EP2013/074012 patent/WO2014079787A1/en not_active Ceased
- 2013-11-18 HK HK15108069.2A patent/HK1207317A1/xx unknown
- 2013-11-18 JP JP2015543399A patent/JP2016505534A/ja active Pending
- 2013-11-18 CN CN201380060294.0A patent/CN104812387A/zh active Pending
- 2013-11-18 KR KR1020157016208A patent/KR20150085538A/ko not_active Ceased
- 2013-11-18 RU RU2015120217A patent/RU2015120217A/ru not_active Application Discontinuation
- 2013-11-18 TW TW102141946A patent/TW201425312A/zh unknown
- 2013-11-18 EP EP13795705.6A patent/EP2922540A1/en not_active Withdrawn
- 2013-11-18 MX MX2015006364A patent/MX2015006364A/es unknown
- 2013-11-18 AR ARP130104234A patent/AR093519A1/es unknown
-
2015
- 2015-05-20 US US14/717,109 patent/US9657014B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2838857C2 (ru) * | 2019-01-03 | 2025-04-22 | Юниверсити Оф Питтсбург - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Способы и материалы для повышения уровней полипептида фактора транскрипции eb |
| US12286442B2 (en) | 2019-01-03 | 2025-04-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
Also Published As
| Publication number | Publication date |
|---|---|
| AR093519A1 (es) | 2015-06-10 |
| US20150252044A1 (en) | 2015-09-10 |
| HK1207317A1 (en) | 2016-01-29 |
| EP2922540A1 (en) | 2015-09-30 |
| CN104812387A (zh) | 2015-07-29 |
| JP2016505534A (ja) | 2016-02-25 |
| BR112015011094A2 (pt) | 2017-07-11 |
| TW201425312A (zh) | 2014-07-01 |
| WO2014079787A1 (en) | 2014-05-30 |
| US9657014B2 (en) | 2017-05-23 |
| MX2015006364A (es) | 2015-10-05 |
| KR20150085538A (ko) | 2015-07-23 |
| CA2890685A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015120217A (ru) | Замещенные 1,6-нафтиридины | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| JP2013539777A5 (OSRAM) | ||
| RU2015150946A (ru) | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения | |
| JP2016517878A5 (OSRAM) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2019523233A5 (OSRAM) | ||
| JP2017502940A5 (OSRAM) | ||
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| JP2006502112A5 (OSRAM) | ||
| JP2017525757A5 (OSRAM) | ||
| US20170143712A1 (en) | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | |
| JP2019514878A5 (OSRAM) | ||
| RU2012137956A (ru) | Производные пиперидинов | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| CA3071760A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| JP2012501312A5 (OSRAM) | ||
| WO2014164767A1 (en) | Novel compounds and compositions for inhibition of fasn | |
| JP2019505595A5 (OSRAM) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| RU2011114487A (ru) | Гетероциклические соединения как ингибиторы протеинкиназы | |
| JP2017530185A5 (OSRAM) | ||
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180329 |